Cell-of-origin chromatin organization shapes the mutational landscape of cancer
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
An analysis of cell-type-specific epigenomic features reveals a relationship between epigenomic and mutational profiles; chromatin characteristics can explain a large proportion of mutational variance in cancer genomes and the mutational distribution can identify the probable cell type from which a given cancer originated from. Genomic studies have shown that different cancer types vary substantially in the local density and types of somatic mutations. This has been explained not only by differences in DNA sequence but also by other features including epigenetic organization. Shamil Sunyaev and colleague now compare mutation densities to detailed epigenetic profiles of different cell types and tissues. They demonstrate that epigenomic features of a given cell type or tissue in which a cancer arises are much stronger determinants of mutational profiles than other properties. Conversely, the findings make it possible to deduce information on the possible tissue-of-origin of a tumour based on its mutational landscape. Cancer is a disease potentiated by mutations in somatic cells. Cancer mutations are not distributed uniformly along the human genome. Instead, different human genomic regions vary by up to fivefold in the local density of cancer somatic mutations1, posing a fundamental problem for statistical methods used in cancer genomics. Epigenomic organization has been proposed as a major determinant of the cancer mutational landscape1,2,3,4,5. However, both somatic mutagenesis and epigenomic features are highly cell-type-specific6,7. We investigated the distribution of mutations in multiple independent samples of diverse cancer types and compared them to cell-type-specific epigenomic features. Here we show that chromatin accessibility and modification, together with replication timing, explain up to 86% of the variance in mutation rates along cancer genomes. The best predictors of local somatic mutation density are epigenomic features derived from the most likely cell type of origin of the corresponding malignancy. Moreover, we find that cell-of-origin chromatin features are much stronger determinants of cancer mutation profiles than chromatin features of matched cancer cell lines. Furthermore, we show that the cell type of origin of a cancer can be accurately determined based on the distribution of mutations along its genome. Thus, the DNA sequence of a cancer genome encompasses a wealth of information about the identity and epigenomic features of its cell of origin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutation rates vary in different parts of the genome, at different stages of the life cycle and in diseases such as cancer, where they depend on the cell of origin, environmental exposure and cancer type [60][61][62] .”
From Advances in epigenetics link genetics to the environment and disease (2019) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breiman, L. (2001) · Machine Learning · doi:10.1023/a:1010933404324 · Cited by 133,538
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Integrative analysis of 111 reference human epigenomes
Roadmap Epigenomics Consortium, Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi, A., Kheradpour, P., Zhang, Z., Wang, J., et al. (2015) · Nature · doi:10.1038/nature14248 · Cited by 6,368
Self-citationMutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationThe Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
Self-citationComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Self-citationPermutation importance: a corrected feature importance measure
Altmann, A., Toloşi, L., Sander, O., & Lengauer, T. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq134 · Cited by 2,843
The accessible chromatin landscape of the human genome
Thurman, R. E., Rynes, E., Humbert, R., Vierstra, J., Maurano, M. T., Haugen, E., Sheffield, N. C., Stergachis, A. B., Wang, H., Vernot, B., et al. (2012) · Nature · doi:10.1038/nature11232 · Cited by 2,679
Self-citation
Cited by
Items 101–200 of 548
Passenger Hotspot Mutations in Cancer
Hess, J. M., Bernards, A., Kim, J., Miller, M. L., Taylor-Weiner, A. N., Haradhvala, N. J., Lawrence, M. S., & Getz, G. A. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.002 · Cited by 99
Self-citationChromatin organisation and cancer prognosis: a pan-cancer study
Kleppe, A., Albregtsen, F., Vlatkovic, L., Pradhan, M., Nielsen, B., Hveem, T. S., Askautrud, H. A., Kristensen, G. B., Nesbakken, A., Trovik, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30899-9 · Cited by 90
Shinde, J., Bayard, Q., Imbeaud, S., Hirsch, T. Z., Liu, F., Renault, V., Zucman‐Rossi, J., & Letouzé, É. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty388 · Cited by 86
Epigenetic modifications affect the rate of spontaneous mutations in a pathogenic fungus
Habig, M., Lorrain, C., Feurtey, A., Komluski, J., & Stukenbrock, E. H. (2021) · Nature Communications · doi:10.1038/s41467-021-26108-y · Cited by 92
Carcinogen susceptibility is regulated by genome architecture and predicts cancer mutagenesis
García‐Nieto, P. E., Schwartz, E. K., King, D. A., Paulsen, J., Collas, P., Herrera, R. E., & Morrison, A. J. (2017) · The EMBO Journal · doi:10.15252/embj.201796717 · Cited by 85
“As previously reported, mutation heterogeneity across the genome of advanced cancers, including malignant melanoma, is largely correlated with heterochromatin features of the primary cell of origin rather than cancer cells (Polak et al , 2015).”
Franco, I., Helgadottir, H. T., Moggio, A., Larsson, M., Vrtačnik, P., Johansson, A., Norgren, N., Lundin, P., Mas-Ponte, D., Nordström, J., et al. (2019) · Genome Biology · doi:10.1186/s13059-019-1892-z · Cited by 82
Chrysafis, I., Mallinis, G., Gitas, I. Z., & Tsakiri–Strati, M. (2017) · Remote Sensing of Environment · doi:10.1016/j.rse.2017.07.018 · Cited by 90
Nguyen, L., van Hoeck, A., & Cuppen, E. P. J. G. (2022) · Nature Communications · doi:10.1038/s41467-022-31666-w · Cited by 96
“Fourth, the number of SBSs in each 1Mb bin across the genome (n=3071) was calculated to determine the RMD [17].”
MethodCell type-specific properties and environment shape tissue specificity of cancer genes
Schaefer, M. H., & Serrano, L. (2016) · Scientific Reports · doi:10.1038/srep20707 · Cited by 100
Genome-wide mapping of somatic mutation rates uncovers drivers of cancer
Sherman, M. A., Yaari, A. U., Priebe, O., Dietlein, F., Loh, P.-R., & Berger, B. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01353-8 · Cited by 80
Mutational Biases Drive Elevated Rates of Substitution at Regulatory Sites across Cancer Types
Kaiser, V. B., Taylor, M. S., & Semple, C. A. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1006207 · Cited by 82
“Regions of open chromatin have previously been shown to mutate at a decreased rate [13,28,30,31], presumably as such regions are more accessible to the DNA repair machinery.”
Araya, C. L., Cenik, C., Reuter, J., Kiss, G., Pande, V. S., Snyder, M. P., & Greenleaf, W. J. (2015) · Nature Genetics · doi:10.1038/ng.3471 · Cited by 89
OncodriveCLUSTL: a sequence-based clustering method to identify cancer drivers
Arnedo-Pac, C., Mularoni, L., Muiños, F., González-Pérez, A., & López-Bigas, N. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz501 · Cited by 91
Synthetic lethal strategies for the development of cancer therapeutics
Ngoi, N. Y. L., Gallo, D., Torrado, C., Nardo, M., Durocher, D., & Yap, T. A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00966-z · Cited by 88
“Mutations in genes involved in reading, adding or removing epigenetic modifications and affecting chromatin regulation and organization have been detected in up to 50% of cancers 236,237 .”
Bladder cancer stem cells: clonal origin and therapeutic perspectives
Li, Y., Lin, K., Yang, Z., Han, N., Quan, X., Guo, X., & Li, C. (2017) · Oncotarget · doi:10.18632/oncotarget.19112 · Cited by 85
“Histone modification and chromatin rearrangement mutations usually exist in CSCs [81], promoting tumour initiation in different mechanisms [82]such as influencing the genome integrity [83]or leading to epigenetic reprogramming in iPS [84].”
BackgroundThree-dimensional genome architecture and emerging technologies: looping in disease
Mishra, A., & Hawkins, R. D. (2017) · Genome Medicine · doi:10.1186/s13073-017-0477-2 · Cited by 87
“As a result, the fluctuating mutation rate is strongly related to changes in DNA accessibility [72], and it was recently reported that the mutational contours of cancer are largely determined by the chromatin landscape of the cell type of origin [73].”
BackgroundAir pollution and DNA methylation alterations in lung cancer: A systematic and comparative study
Jiang, C., He, S.-W., Zhang, Y., Duan, H., Huang, T., Huang, Y., Li, G., Wang, P., Ma, L., Zhou, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13622 · Cited by 76
“However, global hypomethylation correlates with genomic instability [17], and abnormal DNA methylation may increase the susceptibility of gene mutations caused by carcinogens [40, 52].”
BackgroundBrinkman, A. B., Nik‐Zainal, S., Simmer, F., Rodríguez-González, F. G., Smid, M., Alexandrov, L. B., Butler, A. P., Martin, S., Davies, H. R., Głodzik, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09828-0 · Cited by 87
Scales and mechanisms of somatic mutation rate variation across the human genome
Supek, F., & Lehner, B. (2019) · DNA Repair · doi:10.1016/j.dnarep.2019.102647 · Cited by 82
Mazrooei, P., Kron, K. J., Zhu, Y., Zhou, S., Grillo, G., Mehdi, T., Ahmed, M., Severson, T., Guilhamon, P., Armstrong, N. S., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.005 · Cited by 76
Uo, T., Sprenger, C. C. T., & Plymate, S. R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.580617 · Cited by 88
“The phenotypic traits in the original environment often determine the molecular processes that drive the progression to advanced and metastatic tumors (4, 5).”
BackgroundContrasting somatic mutation patterns in aging human neurons and oligodendrocytes
Ganz, J., Luquette, L. J., Bizzotto, S., Miller, M. B., Zhou, Z., Bohrson, C. L., Jin, H., Tran, A. V., Viswanadham, V., McDonough, G. A., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.025 · Cited by 91
“…tumors Patterns of somatic mutation in cancer often contain sufficient information to identify the cell type from which a tumor emerged 58 ; thus, we explored whether our normal OL sSNV densities resembled those from a large collection of cancer WGS data from the Pan-Cancer Analysis…”
BackgroundAbyzov, A., Tomasini, L., Zhou, B., Vasmatzis, N., Coppola, G., Amenduni, M., Pattni, R., Wilson, M., Gerstein, M., Weissman, S., et al. (2017) · Genome Research · doi:10.1101/gr.215517.116 · Cited by 75
“Somatic SNVs in various cancers were shown to have strong negative correlation with prominent epigenomic marks, such that histone modifications and DNase hypersensitive sites can be used as good predictors of SNV density (Polak et al. 2015).”
BackgroundIdentification of Cancer Drivers at CTCF Insulators in 1,962 Whole Genomes
Liu, E. M., Martinez‐Fundichely, A., Diaz, B. J., Aronson, B. E., Cuykendall, T. N., MacKay, M. J., Dhingra, P., Wong, E. W. P., Chi, P., Apostolou, E., et al. (2019) · Cell Systems · doi:10.1016/j.cels.2019.04.001 · Cited by 94
“reported co-variates of mutation rates, including replication timing, mutational sequence context, DNase I hypersensitive sites (DHSs), and histone modification marks (Alexandrov et al., 2013; Polak et al., 2015).”
BackgroundBartlett, T. E., Chindera, K., McDermott, J. R., Breeze, C. E., Cooke, W. R., Jones, A., Reisel, D., Karegodar, S. T., Arora, R., Beck, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms11620 · Cited by 80
Fredriksson, N. J., Elliott, K., Filges, S., Van den Eynden, J., Ståhlberg, A., & Larsson, E. (2017) · PLOS Genetics · doi:10.1371/journal.pgen.1006773 · Cited by 73
Leveraging Distant Relatedness to Quantify Human Mutation and Gene-Conversion Rates
Palamara, P. F., Francioli, L. C., Wilton, P., Genovese, G., Gusev, A., Finucane, H. K., Sankararaman, S., Sunyaev, S. R., de Bakker, P. I. W., Wakeley, J., et al. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.10.006 · Cited by 80
Self-citationSmith, T., Arndt, P. F., & Eyre‐Walker, A. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007254 · Cited by 80
Nucleotide diversity analysis highlights functionally important genomic regions
Tatarinova, T. V., Chekalin, E., Nikolsky, Y., Bruskin, S. A., Chebotarov, D., McNally, K. L., & Alexandrov, N. N. (2016) · Scientific Reports · doi:10.1038/srep35730 · Cited by 75
The Origins of Gastric Cancer From Gastric Stem Cells: Lessons From Mouse Models
Hayakawa, Y., Fox, J. G., & Wang, T. C. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.01.013 · Cited by 75
Sethi, N. S., Kikuchi, O., Duronio, G. N., Stachler, M. D., McFarland, J. M., Ferrer-Luna, R., Zhang, Y., Bao, C., Bronson, R. T., Patil, D. T., et al. (2020) · Nature Genetics · doi:10.1038/s41588-019-0574-9 · Cited by 73
Oxidative stress as an iceberg in carcinogenesis and cancer biology
Toyokuni, S. (2016) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2015.11.025 · Cited by 66
De novo mutations, genetic mosaicism and human disease
Mohiuddin, M., Kooy, R. F., & Pearson, C. E. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.983668 · Cited by 76
“, 2015; Aggarwala and Voight, 2016), apolipoprotein B messenger RNA-editing enzyme catalytic (APOBEC) polypeptide activity (Chan and Gordenin, 2015), and epigenetics (Polak et al., 2015; Rahbari et al., 2016a) have also been reported to affect the mutational landscape.”
BackgroundTissue-independent and tissue-specific patterns of DNA methylation alteration in cancer
Chen, Y., Breeze, C. E., Zhen, S., Beck, S., & Teschendorff, A. E. (2016) · Epigenetics & Chromatin · doi:10.1186/s13072-016-0058-4 · Cited by 65
“First, this mark featured prominently as a predictor of somatic mutation frequency in cancer [19].”
BackgroundMethodPredicting cancer type from tumour DNA signatures
Soh, K. P., Szczurek, E., Sakoparnig, T., & Beerenwinkel, N. (2017) · Genome Medicine · doi:10.1186/s13073-017-0493-2 · Cited by 69
“found a relationship between the chromatin organisation of primary cancer cells and the distribution of mutations along their cancer genome [11].”
BackgroundJordà, M., Díez-Villanueva, A., Mallona, I., Martín, B., Lois, S., Barrera, V., Esteller, M., Vavouri, T., & Peinado, M. A. (2016) · Genome Research · doi:10.1101/gr.207522.116 · Cited by 64
“…et al. 2013) and the increased somatic mutation rates observed in heterochromatic and late replicating regions (Schuster-Böckler and Lehner 2012; Polak et al. 2015) point out that factors regulating high-order chromatin architecture (Dekker et al. 2013; Gómez-Díaz and Corces 2014; Feinberg et…”
BackgroundIdentification of FOXM1 as a specific marker for triple‑negative breast cancer
Tan, Y., Wang, Q., Xie, Y., Qiao, X., Zhang, S., Wang, Y., Yang, Y., & Zhang, B. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4598 · Cited by 66
“A recent study identified that certain cancer genes are only involved in the development of specific cancer types; however, are rarely identified in other types of cancer (23).”
BackgroundSasaki, M., & Ogiwara, H. (2020) · Cancer Science · doi:10.1111/cas.14311 · Cited by 66
Evolution of the mutation rate across primates
Chintalapati, M., & Moorjani, P. (2020) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2020.05.028 · Cited by 68
Androgen receptor-binding sites are highly mutated in prostate cancer
Morova, T., McNeill, D. R., Lallous, N., Gönen, M., Dalal, K., Wilson, D. M., Gürsoy, A., Keskin, Ö., & Lack, N. A. (2020) · Nature Communications · doi:10.1038/s41467-020-14644-y · Cited by 66
Not all cancers are created equal: Tissue specificity in cancer genes and pathways
Bianchi, J. J., Zhao, X., Mays, J. C., & Davoli, T. (2020) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2020.01.005 · Cited by 77
Aneuploidy and complex genomic rearrangements in cancer evolution
Baker, T. M., Waise, S., Tarabichi, M., & Loo, P. V. (2024) · Nature Cancer · doi:10.1038/s43018-023-00711-y · Cited by 72
“In fact, most of the variance in SNV and indel mutation rates along the cancer genome can be explained by local tissue-specific chromatin density and mismatch repair 3,4 .”
Álvarez‐Álvarez, M. M., Biayna, J., & Supek, F. (2022) · Nature Communications · doi:10.1038/s41467-022-32285-1 · Cited by 68
Verhagen, M. P., Joosten, R., Schmitt, M., Välimäki, N., Sacchetti, A., Rajamäki, K., Choi, J., Procopio, P., Silva, S. N., van der Steen, B., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01801-y · Cited by 67
“Similar to previous work 51,52 , the human reference genome (hg38) was processed in nonoverlapping windows of 1 million base pairs.”
ResultCombined burden and functional impact tests for cancer driver discovery using DriverPower
Shuai, S., PCAWG Drivers and Functional Interpretation Working Group, Abascal, F., Amin, S. B., Bader, G. D., Bandopadhayay, P., Barenboim, J., Beroukhim, R., Bertl, J., Boroevich, K. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13929-1 · Cited by 59
Self-citationThe epigenetics of tumour initiation: cancer stem cells and their chromatin
Avgustinova, A., & Benitah, S. A. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2016.01.003 · Cited by 58
DNA methylation and hormone receptor status in breast cancer
Benevolenskaya, E. V., Islam, A. B. M. M. K., Ahsan, H., Kibriya, M. G., Jasmine, F., Wolff, B., Al‐Alem, U., Wiley, E. L., Kajdacsy‐Balla, A., Macias, V., et al. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0184-7 · Cited by 62
“Recent effort towards integrated view of epigenomic features and transcriptome has provided important insights into population-based molecular subgrouping in several cancer types [24].”
BackgroundLeblanc, V., & Marra, M. A. (2015) · Cancers · doi:10.3390/cancers7030869 · Cited by 66
The dark side of the human genome
Chi, K. R. (2016) · Nature · doi:10.1038/538275a · Cited by 66
Yan, K., Lou, S., & Gerstein, M. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005647 · Cited by 65
“Recently, it has been reported that epigenomic features shape the mutational landscape of cancer [24].”
BackgroundNon-coding genetic variation in cancer
Cuykendall, T. N., Rubin, M. A., & Khurana, E. (2017) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2016.12.017 · Cited by 62
Passenger mutations accurately classify human tumors
Salvadores, M., Mas-Ponte, D., & Supek, F. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006953 · Cited by 64
“The RMD on the other hand describes the epigenome organization in the cell-of-origin [26,27].”
The origin of human mutation in light of genomic data
Seplyarskiy, V. B., & Sunyaev, S. R. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00376-2 · Cited by 67
Self-citationAsada, K., Kaneko, S., Takasawa, K., Machino, H., Takahashi, S., Shinkai, N., Shimoyama, R., Komatsu, M., & Hamamoto, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.666937 · Cited by 57
“For example, the mutational landscape of melanoma is best correlated with the epigenetic pro fi le of skin melanocytes than skin fi broblasts or skin keratinocytes, suggesting the true cell-of-origin of melanoma (126).”
BackgroundGelato, K. A., Adler, D., Ocker, M., & Haendler, B. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1134490 · Cited by 54
“epigenome roadmap for normal and diseased tissue will be instrumental to enable this.[183,184] This is likely to impact the design of clinical trials and will”
BackgroundMethodLeukaemia cell of origin identified by chromatin landscape of bulk tumour cells
George, J., Uyar, A., Young, K. A., Kuffler, L., Waldron-Francis, K., Márquez, E. J., Ucar, D., & Trowbridge, J. J. (2016) · Nature Communications · doi:10.1038/ncomms12166 · Cited by 57
“Recently, accurate determination of tumour cell of origin was achieved based on the distribution of mutations along the genome of tumour cells 3 .”
López‐Lázaro, M. (2015) · Oncoscience · doi:10.18632/oncoscience.159 · Cited by 51
“compared mutation densities to epigenetic profiles of normal and cancer cells from different tissues, and reported findings suggesting that the tissue of origin of a cancer may be accurately predicted based on the distribution of mutations along its genome [5].”
BackgroundBRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma
Liu, F., Jiang, C. C., Yan, X. G., Tseng, H., Wang, C. Y., Zhang, Y. Y., Yari, H., La, T., Farrelly, M. L., Guo, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17704 · Cited by 54
“It is known that there are considerable differences in oncogenic signalling context between melanoma and other cancers [33].”
BackgroundBasal cell of origin resolves neuroendocrine–tuft lineage plasticity in cancer
Ireland, A. S., Xie, D. A., Hawgood, S. B., Barbier, M. W., Zuo, L. Y., Hanna, B. E., Lucas-Randolph, S., Tyson, D. R., Witt, B. L., Govindan, R., et al. (2025) · Nature · doi:10.1038/s41586-025-09503-z · Cited by 56
Fedeles, B. I., & Essigmann, J. M. (2018) · DNA repair · doi:10.1016/j.dnarep.2018.08.008 · Cited by 71
“Many factors contribute to the uneven distribution of mutations; chromatin accessibility (open vs closed chromatin) [34], transcriptional status (transcribed vs non-transcribed strands) [35], replication status (early vs late replicating genes) [35], coding status (regulatory elements vs gene bodies) [36], all shape t…”
BackgroundTopography of mutational signatures in human cancer
Otlu, B., Díaz‐Gay, M., Vermes, I., Bergstrom, E. N., Zhivagui, M., Barnes, M. D., & Alexandrov, L. B. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112930 · Cited by 53
Hotspots of De Novo Point Mutations in Induced Pluripotent Stem Cells
Yoshihara, M., Araki, R., Kasama, Y., Sunayama, M., Abe, M., Nishida, K., Kawaji, H., Hayashizaki, Y., & Murakawa, Y. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.060 · Cited by 48
Merkel cell polyomavirus and associated Merkel cell carcinoma
Yang, J. F., & You, J. (2021) · Tumour Virus Research · doi:10.1016/j.tvr.2021.200232 · Cited by 54
Sanalkumar, R., Dong, R., Lee, L., Xing, Y., Iyer, S., Letovanec, I., Rosa, S. L., Finzi, G., Musolino, E., Papait, R., et al. (2023) · Science Advances · doi:10.1126/sciadv.abo3789 · Cited by 43
Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition
Cai, S. F., Chu, S. H., Goldberg, A. D., Parvin, S., Koche, R. P., Glass, J. L., Stein, E. M., Tallman, M. S., Şen, F., Famulare, C. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1469 · Cited by 54
Sousa, L. B. D. A. E., Jonkers, I. H., Syx, L., Dunkel, I., Chaumeil, J., Picard, C., Forêt, B., Chen, C., Lis, J. T., Heard, É., et al. (2019) · Genome Research · doi:10.1101/gr.245027.118 · Cited by 55
“To identify different combinatorial rule sets that could predict silencing susceptibility, we chose to use Random Forest (RF), a non-parametric machine learning method which has been shown to perform very well in non-linear classification tasks (Polak et al. 2015).”
MethodAssante, G., Chandrasekaran, S., Ng, S., Tourna, A., Chung, C. H., Isse, K. A., Banks, J. L., Soffientini, U., Filippi, C., Dhawan, A., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01071-5 · Cited by 45
“Mutations in epigenetic modifier proteins are commonly found in cancer, even as the initiating mutation [17, 18].”
BackgroundAbedalthagafi, M., Wu, M. P., Merrill, P. H., Du, Z., Woo, T. Y. C., Sheu, S., Hurwitz, S., Ligon, K. L., & Santagata, S. (2016) · The Journal of Pathology · doi:10.1002/path.4682 · Cited by 52
“Once tumours begin to develop, cell lineage information and epigenomic patterns are often faithfully maintained in tumour cells [4].”
BackgroundMultiple cellular origins and molecular evolution of intrahepatic cholangiocarcinoma
Wei, M., Lü, L., Lin, P., Chen, Z., Quan, Z., & Tang, Z. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.02.038 · Cited by 48
Cofré, J., & Abdelhay, E. S. F. W. (2017) · The Scientific World JOURNAL · doi:10.1155/2017/3578090 · Cited by 45
“Accordingly, mutations distributions in the genome, in several independent samples and various types of cancer, demonstrated that chromatin accessibility, their epigenetic modifications (epigenomics organization), and replication time should explain up to 86% of the rate variance of genome mutation studied in differen…”
BackgroundIntegrated epigenomic profiling reveals endogenous retrovirus reactivation in renal cell carcinoma
Siebenthall, K. T., Miller, C. P., Vierstra, J. D., Mathieu, J., Tretiakova, M., Reynolds, A. P., Sandstrom, R. S., Rynes, E., Neph, S. J., Haugen, E., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.01.063 · Cited by 45
“However, the complexity of these deep epigenomic mapping methods has focused their initial application to mouse tissues [5], cultured human cell lines [6], whole adult and fetal human tissues [7], hematopoietic neoplasms (where both malignant and normal cells of origin are readily obtained [8,9]), and a limited number…”
BackgroundSelf-citationKlein, S., Quaas, A., Noh, K., Cartolano, M., Abedpour, N., Mauch, C., Quantius, J., Reinhardt, H. C., Buettner, R., Peifer, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1899 · Cited by 47
“Recently, it has been demonstrated that variations of the local mutation rate are specific to the cell of origin (15, 17).”
BackgroundJoaquim Bellmunt, B. (2018) · Biomedicines · doi:10.3390/biomedicines6030085 · Cited by 41
“Histone modification and chromatin rearrangement mutations are frequently present in CSCs [72], and promote tumor initiation [73] influencing genome integrity [74] or leading to epigenetic reprogramming [75].”
BackgroundAgarwal, I., & Przeworski, M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1900714116 · Cited by 45
Schipper, L. J., Samsom, K. G., Snæbjörnsson, P., Battaglia, T., Bosch, L. J. W., Lalezari, F., Priestley, P., Shale, C., van den Broek, A. J., Jacobs, N., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100611 · Cited by 45
“7 As such, regional mutational density across the genome has diagnostic power.”
Altered primary chromatin structures and their implications in cancer development
Ferraro, A. (2016) · Cellular Oncology · doi:10.1007/s13402-016-0276-6 · Cited by 45
The Discovery of Biomarkers in Cancer Immunotherapy
George, A. P., Kuzel, T. M., Zhang, Y., & Zhang, B. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.03.015 · Cited by 45
Rheinbay, E., Nielsen, M. M., Abascal, F., Tiao, G., Hornshøj, H., Hess, J. M., Pedersen, R. I., Feuerbach, L., Sabarinathan, R., Madsen, T., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/237313 · Cited by 40
Self-citationChemical Carcinogenesis Models of Cancer: Back to the Future
McCreery, M. Q., & Balmain, A. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-122002 · Cited by 43
“Carcinogen-induced mutations in human cancers are clustered in regions of closed chromatin, resulting in mutation patterns that depend on the tissue in which tumors arise (Polak et al. 2015).”
BackgroundAvgustinova, A., Symeonidi, A., Castellanos‐Martín, A., Urdiroz-Urricelqui, U., Solé‐Boldo, L., Martín, M., Pérez-Rodríguez, I., Prats, N., Lehner, B., Supek, F., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0233-x · Cited by 45
From Genotype to Phenotype: Through Chromatin
Romanowska, J., & Joshi, A. (2019) · Genes · doi:10.3390/genes10020076 · Cited by 41
Beyond the exome: the role of non-coding somatic mutations in cancer
Piraino, S. W., & Furney, S. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv561 · Cited by 44
“In addition, the tissue specificity of mutation rate variation has been used to develop a model that can classify tumours based on tissue of origin [25].”
BackgroundMethodPerturbations in the Replication Program Contribute to Genomic Instability in Cancer
Blumenfeld, B., Ben‐Zimra, M., & Simon, I. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061138 · Cited by 42
“In fact, it has been shown that cell type specific replication timing can best explain the mutational landscape of different cancer tissues [127,178].”
BackgroundNassir, N., Bankapur, A., Samara, B., Ali, A. Y., Ahmed, A., Inuwa, I. M., Zarrei, M., Shabestari, S. A. S., Albanna, A., Howe, J., et al. (2021) · Human Genomics · doi:10.1186/s40246-021-00368-7 · Cited by 41
“In addition, we conducted replication-timing analysis as it has been reported that somatic mutations discovered in cancers [32, 33] and ASD gene mutations [34] are associated with late DNA replication.”
MethodContext-Dependent Roles of Claudins in Tumorigenesis
Li, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.676781 · Cited by 47
Contributing factors to the oxidation-induced mutational landscape in human cells
Cordero, C., Mehta, K. P. M., Weaver, T., Ling, J. A., Freudenthal, B., Cortez, D., & Roberts, S. A. (2024) · Nature Communications · doi:10.1038/s41467-024-55497-z · Cited by 35
Juul, M., Bertl, J., Guo, Q., Nielsen, M. M., Świtnicki, M., Hornshøj, H., Madsen, T., Hobolth, A., & Pedersen, J. S. (2017) · eLife · doi:10.7554/elife.21778 · Cited by 39
“However, modeling the background mutation rate is complicated as it varies along the genome with a large degree of heterogeneity (Lawrence et al., 2013; Polak et al., 2015; Alexandrov et al., 2013).”
BackgroundTranscriptional regulators and alterations that drive melanoma initiation and progression
Gupta, R., Janoštiak, R., & Wajapeyee, N. (2020) · Oncogene · doi:10.1038/s41388-020-01490-x · Cited by 46
Use of signals of positive and negative selection to distinguish cancer genes and passenger genes
Bányai, L., Trexler, M., Kerekes, K., Csuka, O., & Patthy, L. (2021) · eLife · doi:10.7554/elife.59629 · Cited by 39
Molecular pathways in viral hepatitis-associated liver carcinogenesis: An update
Elpek, G. Ö. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i19.4890 · Cited by 39
The Unexpected Noncatalytic Roles of Histone Modifiers in Development and Disease
Aubert, Y., Egolf, S., & Capell, B. C. (2019) · Trends in Genetics · doi:10.1016/j.tig.2019.06.004 · Cited by 42
“In fact, epigenome profiling of the chromatin landscape in tumors of unknown cell of origin can provide a more accurate determination of the tissue of origin than does sequencing the tumor itself [7].”
BackgroundIdentifying predictors of glioma evolution from longitudinal sequencing
Mu, Q., Chai, R., Pang, B., Yang, Y., Liu, H., Zhao, Z., Bao, Z., Song, D., Zhu, Z., Yan, M., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh4181 · Cited by 39
Organization of DNA damage, excision repair, and mutagenesis in chromatin: A genomic perspective
Mao, P., & Wyrick, J. J. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.102645 · Cited by 39
“Consistent with this finding, a significant correlation is observed between melanoma mutation density and chromatin accessibility in melanocyte cells [43].”
BackgroundExamining clustered somatic mutations with SigProfilerClusters
Bergstrom, E. N., Kundu, M., Tbeileh, N., & Alexandrov, L. B. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac335 · Cited by 39
Contrasting Determinants of Mutation Rates in Germline and Soma
Chen, C., Qi, H., Shen, Y., Pickrell, J. K., & Przeworski, M. (2017) · Genetics · doi:10.1534/genetics.117.1114 · Cited by 41
Hybrid Stomach-Intestinal Chromatin States Underlie Human Barrett’s Metaplasia
Singh, H., Ha, K., Hornick, J. L., Madha, S., Cejas, P., Jajoo, K., Singh, P. N. P., Polak, P. P., Lee, H., & Shivdasani, R. A. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.05.057 · Cited by 36
“24 Chromatin states might hence point to cellular sources of BE with more clarity than other methods possible in human tissues and, in individual cells, show the cis -regulatory basis for cellular diversity.”
Self-citationYazdi, P. G., Pedersen, B., Taylor, J. F., Khattab, O. S., Chen, Y., Chen, Y., Jacobsen, S. E., & Wang, P. H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136574 · Cited by 36
“This is in line with recent data from the Roadmap Epigenomics Project, which demonstrated cell-type specific cancer mutations are influenced by cell-type specific chromatin architecture[53].”
ResultGermline DNA replication timing shapes mammalian genome composition
Yehuda, Y., Blumenfeld, B., Mayorek, N., Makedonski, K., Vardi, O., Cohen‐Daniel, L., Mansour, Y., Sebban, S., Masika, H., Farago, M., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky610 · Cited by 39
“Using the correct tissue data improves RViMR estimation (58,59) and accordingly, germ cell RT data is especially important for estimation of germline RViMR.”
BackgroundMethodSelf-citationHa, K., Fujita, M., Karlić, R., Yang, S., Xue, R., Zhang, C., Bai, F., Zhang, N., Hoshida, Y., Polak, P. P., et al. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e03350 · Cited by 33
“Previous publication showed that gene expression data can explain regional somatic mutation variance, albeit at a lower level compared with the chromatin features (Polak et al., 2015).”
BackgroundMethodResultInfluentialSelf-citationGenetic Control of Alternative Splicing and its Distinct Role in Colorectal Cancer Mechanisms
Zhang, M., Chen, C., Lu, Z., Cai, Y., Li, Y., Zhang, F., Liu, Y., Chen, S., Zhang, H., Yang, S., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.07.019 · Cited by 33
Metadata
- Authors
- Polak, P., Karlić, R., Koren, A., Thurman, R., Sandstrom, R., Lawrence, M. S., Reynolds, A., Rynes, E., Vlahoviček, K., Stamatoyannopoulos, J. A., & Sunyaev, S. R.
- Affiliations
- Broad Institute (US)
- University of Zagreb (HR)
- University of Washington (US)
- Corresponding author
- Stamatoyannopoulos, John A.
- Sunyaev, Shamil R.
- ORCID
- Venue
- Nature
- Published
- 2015-02-18
- Volume
- 518
- Issue
- 7539
- Pages
- 360-364
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4405175
- OpenAlex
- W2086239585
- Cited by
- 557
- References
- 29
- Citations by year
- 2026: 22 · 2025: 31 · 2024: 41 · 2023: 41 · 2022: 46 · 2021: 56 · 2020: 55 · 2019: 62 · 2018: 46 · 2017: 60 · 2016: 65 · 2015: 29
- FWCI
- 22.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (HL53750)
- National Heart, Lung, and Blood Institute (P01HL053750, P01 HL53750)
- National Institute of Mental Health (R01MH101244)
- National Human Genome Research Institute (U54HG007010)
- National Cancer Institute (U54CA143874)
- National Institute of Environmental Health Sciences (U01ES017156)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- cell of origin, chromatin accessibility, chromatin modification, DNA replication timing, somatic mutations, mutation density, tissue of origin prediction, cancer cell lines
- MeSH terms
- Chromatin, Humans, Melanocytes, Melanoma, Mutation, Neoplasms, Organ Specificity, Genome, Human, DNA Replication Timing, Epigenesis, Genetic, Cell Line, Tumor, Epigenomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.